Michael Yee
Stock Analyst at Jefferies
(3.08)
# 1,341
Out of 5,044 analysts
78
Total ratings
43.4%
Success rate
14.08%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALXO ALX Oncology Holdings | Upgrades: Buy | $2 → $3 | $1.59 | +88.68% | 5 | Mar 6, 2025 | |
| KOD Kodiak Sciences | Upgrades: Buy | $20 | $18.93 | +5.65% | 3 | Dec 9, 2024 | |
| BIIB Biogen | Downgrades: Hold | $250 → $180 | $147.86 | +21.74% | 5 | Dec 9, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $500 → $550 | $417.21 | +31.83% | 4 | Dec 9, 2024 | |
| AMGN Amgen | Maintains: Buy | $380 | $291.77 | +30.24% | 5 | Nov 12, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $40 → $45 | $16.25 | +176.92% | 2 | Nov 1, 2024 | |
| MRNA Moderna | Maintains: Hold | $65 → $55 | $24.70 | +122.67% | 8 | Oct 15, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $35 | $19.52 | +79.30% | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $40 | $27.61 | +44.88% | 1 | Sep 13, 2024 | |
| AXON Axon Enterprise | Initiates: Buy | $385 | $759.44 | -49.30% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1.4 → $10 | $5.26 | +90.11% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $6.25 | -52.00% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $30 | $24.77 | +21.11% | 2 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $16.81 | +18.98% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $20 | $29.27 | -31.67% | 3 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 → $75 | $8.61 | +771.08% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $7.37 | +307.06% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $32.85 | +97.87% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,875 → $1,125 | $10.91 | +10,211.64% | 2 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $2.87 | +945.30% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $10.65 | +181.69% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $30.99 | +287.22% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $70 → $75 | $21.15 | +254.61% | 2 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $77.05 | -61.06% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $19.78 | +289.28% | 2 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $118.50 | - | 3 | Jan 26, 2018 |
ALX Oncology Holdings
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $1.59
Upside: +88.68%
Kodiak Sciences
Dec 9, 2024
Upgrades: Buy
Price Target: $20
Current: $18.93
Upside: +5.65%
Biogen
Dec 9, 2024
Downgrades: Hold
Price Target: $250 → $180
Current: $147.86
Upside: +21.74%
Vertex Pharmaceuticals
Dec 9, 2024
Upgrades: Buy
Price Target: $500 → $550
Current: $417.21
Upside: +31.83%
Amgen
Nov 12, 2024
Maintains: Buy
Price Target: $380
Current: $291.77
Upside: +30.24%
Denali Therapeutics
Nov 1, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $16.25
Upside: +176.92%
Moderna
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $24.70
Upside: +122.67%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $19.52
Upside: +79.30%
Oruka Therapeutics
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $27.61
Upside: +44.88%
Axon Enterprise
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $759.44
Upside: -49.30%
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $5.26
Upside: +90.11%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $6.25
Upside: -52.00%
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $24.77
Upside: +21.11%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $16.81
Upside: +18.98%
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $29.27
Upside: -31.67%
Jan 6, 2023
Upgrades: Buy
Price Target: $63 → $75
Current: $8.61
Upside: +771.08%
Nov 15, 2021
Initiates: Buy
Price Target: $30
Current: $7.37
Upside: +307.06%
Mar 2, 2021
Initiates: Buy
Price Target: $65
Current: $32.85
Upside: +97.87%
Mar 2, 2021
Downgrades: Hold
Price Target: $1,875 → $1,125
Current: $10.91
Upside: +10,211.64%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $2.87
Upside: +945.30%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $10.65
Upside: +181.69%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $30.99
Upside: +287.22%
Oct 12, 2020
Upgrades: Buy
Price Target: $70 → $75
Current: $21.15
Upside: +254.61%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $77.05
Upside: -61.06%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $19.78
Upside: +289.28%
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $118.50
Upside: -